Jazz Pharmaceuticals JAZZ EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's EBITDA?
- Jazz Pharmaceuticals (JAZZ) reported EBITDA of $518M in Q1 2026.
- How has Jazz Pharmaceuticals's EBITDA changed year-over-year?
- Jazz Pharmaceuticals's EBITDA increased by 1238.5% year-over-year, from -$45.5M to $518M.
- What is the long-term trend for Jazz Pharmaceuticals's EBITDA?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EBITDA has grown at a 56.1% compound annual growth rate (CAGR), from $196.98M to $749.43M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.